Publications by authors named "Shaun Cooper"

7 Publications

  • Page 1 of 1

Evaluation of vitamin D protocol in the neonatal intensive care unit at Rush University Medical Center.

JPEN J Parenter Enteral Nutr 2021 Jun 14. Epub 2021 Jun 14.

Division of Neonatology, Department of Pediatrics, Rush University Medical Center, Chicago, Illinois, USA.

Background: In 2017, the neonatal intensive care unit (NICU) at Rush University Medical Center (RUMC) implemented a protocol to provide individualized vitamin D supplementation dosing for very low-birth-weight (VLBW) and very preterm infants. This study evaluated the association of demographic and socioeconomic factors, vitamin D dose, and health indicators, including bone mineral status, measured by alkaline phosphatase and phosphorus levels; linear growth velocity; and occurrence of fractures.

Method: This retrospective cross-sectional study included 227 VLBW or very preterm infants (34 VLBW, 12 very preterm, and 181 VLBW and very preterm) born in and discharged from the RUMC NICU between February 1, 2017, and October 31, 2019. Vitamin D dose was classified as adjusted (supplemental dose of 800 IU/day, n = 169) or standard (recommended dose of 400 IU/day, n = 58), per the protocol. Binary logistic and linear regression models were constructed to test the associations between infant and maternal characteristics and vitamin D dose group and between vitamin D dose group and health indicators.

Results: The analysis found a statistically significant association between maternal age, gestational age, infant birth weight, and race/ethnicity and receipt of an adjusted vitamin D dose. No significant associations were found between health indicators and vitamin D dose.

Conclusion: Sociodemographic factors may influence vitamin D deficiency in VLBW and very preterm infants in the NICU. At this time, there is insufficient evidence to support a tailored approach, but further research in this area is warranted.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/jpen.2138DOI Listing
June 2021

Squamous Cell Carcinoma in Hidradenitis Suppurativa Lesions Following Tumor Necrosis Factor α Inhibitors.

Cutis 2021 Apr;107(4):E5-E7

Dr. Cooper is from the Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire. Drs. Cowdrey, Linos, and Lefferts are from the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. Dr. Cowdrey is from the Section of Dermatology, and Drs. Linos and Lefferts are from the Department of Pathology and Laboratory Medicine, Dermatopathology Division. Dr. Basic is from the James A. Haley Veterans Hospital, Tampa, and the Department of Dermatology, Morsani College of Medicine, University of South Florida, Tampa.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0233DOI Listing
April 2021

Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition.

NPJ Vaccines 2021 Mar 12;6(1):35. Epub 2021 Mar 12.

Flu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.

In the 2013-14 and 2015-16 influenza seasons, reduced vaccine effectiveness (VE) was observed for the H1N1 component of the FluMist quadrivalent live attenuated influenza vaccine (QLAIV) in the USA, leading to loss of Advisory Committee on Immunization Practices recommendation. Here we demonstrate in ferrets that 2015-16A/H1N1pdm09 vaccine strain A/Bolivia/559/2013 (A/BOL13) is outcompeted in trivalent (TLAIV) and QLAIV formulations, leading to reduced protection from wild-type challenge. While monovalent (MLAIV) A/BOL13 provided significant protection from wild-type virus shedding and fever at doses as low as 3.0 log fluorescent focus units (FFU), it failed to provide a similar level of protection in TLAIV or QLAIV formulation, even at a 6.0 log FFU dose. Conversely, clinically effective H1N1 strain A/New Caledonia/20/1999 provided significant protection in MLAIV, TLAIV, and QLAIV formulations. In conclusion, reduced A/BOL13 replicative fitness rendered it susceptible to inter-strain competition in QLAIV, contributing to its reduced VE in the 2015-16 season.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41541-021-00300-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955111PMC
March 2021

Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis.

J Hum Lact 2015 May 17;31(2):237-9. Epub 2015 Feb 17.

Department of Pediatrics, InfantRisk Center, Texas Tech University Health Sciences Center, Amarillo, TX, USA.

High-dose intravenous methylprednisolone, a glucocorticoid with powerful anti-inflammatory activities, has become increasingly important in treating acute relapses of multiple sclerosis (MS). This is a case report of a 36-year-old lactating female who was receiving a 3-day course of high-dose methylprednisolone (1000 mg IV) to treat MS. Breast milk samples were obtained at 1, 2, 4, 8, and 12 hours following a 2-hour intravenous infusion on days 1, 2, and 3. The relative infant dose was found to be 1.45%, 1.35%, and 1.15% for days 1, 2, and 3, respectively. Using the average measured concentrations (C(avg)) for days 1, 2, and 3, the estimated infant exposure was 0.207, 0.194, and 0.164 mg/kg/day, respectively, which is below the recommended dose given to neonates requiring methylprednisolone drug therapy. Infant exposure is low and mothers could continue to breastfeed if treatment with IV methylprednisolone is very brief. However, if the mother wishes to limit infant exposure further, she could wait 2 to 4 hours after IV methylprednisolone administration, thus significantly limiting the amount of drug in the breast milk.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/0890334415570970DOI Listing
May 2015

Transfer of natalizumab into breast milk in a mother with multiple sclerosis.

J Hum Lact 2015 May 13;31(2):233-6. Epub 2015 Jan 13.

Department of Pediatrics, InfantRisk Center, Texas Tech University Health Sciences Center at Amarillo, TX, USA.

Natalizumab (Tysabri) is a recombinant humanized antibody to α4-integrin that is approved by the Food and Drug Administration for the treatment of multiple sclerosis (MS) and Crohn disease. This is a case report of a 28-year-old woman with MS who was taking natalizumab (300 mg intravenously infused over 1 hour every 4 weeks) while breastfeeding her 11.5-month-old daughter 3 times a day. Breast milk samples were collected over a 50-day period after the patient's first drug infusion. The average concentration of natalizumab was 0.93 µg/mL/d, and the relative infant dose was 1.74% of the weight-adjusted maternal dose. Transfer of natalizumab into human milk increased over time and with subsequent injections, with the highest concentration of 2.83 µg/mL at day 50 with a relative infant dose of 5.3%. Because these data suggest continued accumulation of natalizumab in milk, and because we cannot provide an accurate assessment of levels of this drug at 24 weeks (steady state), we are unable to determine safety at this time.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/0890334414566237DOI Listing
May 2015

Transfer of linezolid into breast milk.

J Hum Lact 2014 Nov 6;30(4):410-2. Epub 2014 Aug 6.

School of Medicine, Texas Tech University Health Sciences Center, Amarillo, TX, USA.

Linezolid, a broad-spectrum antibiotic used primarily for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, is the first oxazolidinone approved for clinical use. This is a case report of a 30-year-old woman who was exclusively breastfeeding her infant prior to taking linezolid 600 mg orally every 12 hours to treat a MRSA mastitis. Breast milk samples were obtained over a 12-hour dosing interval on day 1 (after a single dose of therapy) and again on day 14 (at steady state). The relative infant dose at steady state was found to be 15.61% on day 14 of therapy. Using the average concentration at steady state, the estimated infant dose would have been 1.84 mg/kg/day, which is well below the recommended dose given to neonates requiring linezolid drug therapy. The infant did not breastfeed during maternal treatment with linezolid.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/0890334414546045DOI Listing
November 2014

Coordination complexes as molecular glue for immobilization of antibodies on cyclic olefin copolymer surfaces.

Anal Biochem 2014 Jul 8;456:6-13. Epub 2014 Apr 8.

Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, 4072 QLD, Australia; Centre for Advanced Imaging, University of Queensland, Brisbane, 4072 QLD, Australia. Electronic address:

A novel metal-based chelating method has been used to provide an order of magnitude increase in immunoassay performance on cyclic olefin copolymer (COC) plastics compared with passive binding. COCs are hydrophobic, and without surface modification they are often unsuitable for applications where protein adhesion is desired. When interacting with the bare plastic, the majority of the bound proteins will be denatured and become nonfunctional. Many of the surface modification techniques reported to date require costly equipment setup or the use of harsh reaction conditions. Here, we have successfully demonstrated the use of a simple and quick metal chelation method to increase the sensitivity, activity, and efficiency of protein binding to COC surfaces. A detailed analysis of the COC surfaces after activation with the metal complexes is presented, and the immunoassay performance was studied using three different antibody pairs.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2014.03.023DOI Listing
July 2014
-->